Citi analyst Geoff Meacham initiated coverage of Protagonist Therapeutics (PTGX) with a Buy rating and $72 price target The firm cites the potential of rusfertide in polycythemia vera and oral IL-23 in multi-billion inflammation indications for the Buy rating. Citi acknowledges the share outperformance over past three months, but believes rusfertide’s “impressive efficacy” as demonstrated in Phase 3, including improvement in quality of life scores, suggests the drug has “strong potential” in polycythemia vera patients as despite therapeutic advancement there still remains unmet need.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
- Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
- Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
- Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
- Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study